|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM143160214 |
003 |
DE-627 |
005 |
20231223030229.0 |
007 |
tu |
008 |
231223s2003 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0477.xml
|
035 |
|
|
|a (DE-627)NLM143160214
|
035 |
|
|
|a (NLM)14597214
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Selak, Sanja
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Identification of the B-cell epitopes of the early endosome antigen 1 (EEA1)
|
264 |
|
1 |
|c 2003
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 11.12.2003
|
500 |
|
|
|a Date Revised 08.11.2019
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Early endosome antigen 1 (EEA1) is a target autoantigen in patients diagnosed with neurological and other autoimmune conditions. Eighteen of 65 sera (28%) that displayed a vesicular cytoplasmic staining pattern also immunoprecipitated the recombinant EEA1. These 18 sera were selected for further clinical, serological and epitope mapping studies. Thirty-six percent of the 18 patients had neurological diseases. Seventeen sera (94%) reacted with the partial length EEA1 constructs that included the C-terminal zinc finger (+FYVE) and the methyl accepting domain (LeuMA: amino acids 82-1411) in an addressable laser bead assay suggesting that the assay may be used for rapid laboratory detection of anti-EEA1 antibodies. Three of seven sera selected for epitope mapping studies bound to EEA1 peptides represented by amino acids 1096-1125, and two reacted with peptides represented by amino acids 1296-1320. One serum reacted only with the C-terminal peptide 1096-1125. The remaining serum reacted with other EEA1 epitopes. This data was supported by the observations that all the sera immunoprecipitated the C-terminal +FYVE (EEA1 1064-1411) construct, a peptide that also contained the linear epitopes 1096-1140. The limited epitope mapping studies suggest that the sera from patients with non-neurological diseases recognized epitopes in the central and C-terminal EEA1 domains, whereas the patients with neurological disease recognized a more restricted set of epitopes in the C-terminal
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Autoantibodies
|2 NLM
|
650 |
|
7 |
|a Epitopes, B-Lymphocyte
|2 NLM
|
650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
650 |
|
7 |
|a Recombinant Proteins
|2 NLM
|
650 |
|
7 |
|a Vesicular Transport Proteins
|2 NLM
|
650 |
|
7 |
|a early endosome antigen 1
|2 NLM
|
700 |
1 |
|
|a Mahler, Michael
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Miyachi, Kiyomitsu
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fritzler, Mark L
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fritzler, Marvin J
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 109(2003), 2 vom: 15. Nov., Seite 154-64
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:109
|g year:2003
|g number:2
|g day:15
|g month:11
|g pages:154-64
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 109
|j 2003
|e 2
|b 15
|c 11
|h 154-64
|